HC Wainwright Reaffirms Buy Rating for Aethlon Medical (NASDAQ:AEMD)

Aethlon Medical (NASDAQ:AEMD)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $7.00 price objective on the medical equipment provider’s stock.

Separately, StockNews.com upgraded Aethlon Medical to a “sell” rating in a research report on Wednesday, February 19th.

Aethlon Medical Price Performance

Shares of AEMD traded up $0.00 during trading hours on Monday, hitting $0.44. 152,519 shares of the stock were exchanged, compared to its average volume of 2,474,620. The business has a 50-day moving average of $0.66 and a 200-day moving average of $0.50. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $1.85. The firm has a market capitalization of $6.35 million, a P/E ratio of -0.28 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.09. As a group, analysts forecast that Aethlon Medical will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Boothbay Fund Management LLC purchased a new position in Aethlon Medical during the fourth quarter valued at $186,000. Virtu Financial LLC bought a new stake in Aethlon Medical during the fourth quarter worth about $81,000. Sassicaia Capital Advisers LLC purchased a new stake in Aethlon Medical in the fourth quarter worth about $31,000. Allegiance Financial Group Advisory Services LLC purchased a new stake in Aethlon Medical in the fourth quarter worth about $26,000. Finally, Renaissance Technologies LLC bought a new position in shares of Aethlon Medical during the fourth quarter valued at approximately $25,000. Hedge funds and other institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.